Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Mirae Asset Global Investments Co. Ltd. boosted its position in Immunocore Holdings plc (NASDAQ:IMCR) by 28.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,152 shares of the company’s stock after buying an additional 3,623 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Immunocore were worth $1,104,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Immunocore by 103.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after purchasing an additional 426 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Immunocore by 32.9% during the 3rd quarter. IFP Advisors Inc now owns 2,397 shares of the company’s stock valued at $124,000 after buying an additional 594 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock worth $181,000 after buying an additional 674 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Immunocore by 1.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company’s stock valued at $5,639,000 after buying an additional 1,513 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in Immunocore by 26.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock valued at $389,000 after acquiring an additional 1,572 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Stock Up 0.3 %

Shares of IMCR opened at $55.82 on Tuesday. The firm has a market cap of $2.78 billion, a P/E ratio of -48.12 and a beta of 0.89. Immunocore Holdings plc has a 1 year low of $42.21 and a 1 year high of $76.98. The stock has a 50 day simple moving average of $63.38 and a two-hundred day simple moving average of $60.54. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.80 and a quick ratio of 3.77.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The business had revenue of $70.16 million for the quarter, compared to the consensus estimate of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. Immunocore’s revenue for the quarter was up 22.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.63) EPS. On average, analysts forecast that Immunocore Holdings plc will post -1.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and issued a $87.00 price target (up from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Immunocore in a research report on Wednesday, March 6th. JPMorgan Chase & Co. upped their target price on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Canaccord Genuity Group raised their price target on shares of Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a report on Thursday, February 29th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research report on Thursday, April 11th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $80.55.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.